Skip to Main Content

An experimental inflammatory bowel disease medicine that serves as the basis for a partnership between Roivant Sciences and Pfizer met high expectations for a Phase 2 clinical trial data released Wednesday.

In a clinical study of 245 volunteers, the drug, called RVT-3101, helped 32% of trial participants with ulcerative colitis go into remission, compared to 12% in the placebo group. The drug also performed well at the dose Roivant and Pfizer plan to use in Phase 3 testing.


The treatment works by targeting a protein called TL1A that’s linked to inflammation and tissue scarring. It’s the same strategy that competitor Prometheus Biosciences is employing. That company’s drug performed better than expected in Phase 2 data released last month, helping nearly 27% of trial participants enter remission.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.